Drug news
New labeling for anti-smoking Chantix discards suicidal behavior risk - Pfizer
New FDA labeling for Chantix (varenicline) from Pfizer suggests that the anti-smoking medication may not carry the risks of suicidal behavior that first attracted a strong FDA warning more than five years ago. The FDA has now amended the drug's label to include data from a number of recent studies that found little to no evidence of psychiatric problems or suicidal tendencies in patients taking the twice-a-day tablet.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins